王旭先生自 2024 年 6 月起担任本公司董事兼首席执行官。王先生毕业于复旦大学微生物学系，获理学硕士学位，在多家全球领先的制药企业（包括葛兰素史克和武田制药）拥有超过二十年的高级管理及运营经验。自 2021 年起，王先生担任厦门万泰沧海生物科技有限公司总经理，在提升 HPV 疫苗生产能力方面发挥了关键作用。在此之前，王先生于 2012 年至 2020 年在武田制药任职，负责在中国广州和德国辛根商业规模的生产和供应链基地。2001 年至 2012 年，王先生在上海 GSK Biologics 工作，积累了丰富的国际疫苗行业经验。此外，王先生被认定为福建省高层次引进人才，并曾担任国家药品监督管理局（NMPA）药品生产质量管理规范（GMP）培训讲师。

Director

Mr. Xu Wang has served as our director, Chief Executive Officer since June 2024. Mr. Wang has graduated from FUDAN university and obtained the Master of Science degree. He has over twenty years of senior management and strong operational experience from a number of major Pharmaceutical manufacturers, including GSK, Takeda, and others. Mr. Wang has served as the general manager at Xiamen Innovax Co., Ltd. since 2021, where enhancing HPV vaccine production capacity. Prior to that, Mr. Wang worked at Takeda Pharmaceuticals from 2012 to 2020, where he was leading commercial-scale facilities in Guangzhou China and Singen Germany. From 2001 to 2012, Mr. Wang worked at Shanghai GSK Biologics. Mr. Wang was recognized as a Fujian Province Class A Talent and was an NMPA GMP Instructor.